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Background. In Italy nucleic acid testing (NAT) became mandatory for hepatitis C virus (HCV) 
in 2002 and for human immunodeficiency virus (HIV) and hepatitis B virus in 2008. The aim of this 
study was to monitor the incidence and prevalence of HIV and HCV infections in Italian blood donors 
and the current residual risk of these infections after the introduction of NAT. 
Materials and methods. The Italian national blood surveillance system includes data from tests 
used to screen for transfusion-transmissible infections. During the period of this survey (2009-2015), 
the NAT methods used were the transcription-mediated amplification test, for individual donor testing, 
and polymerase chain reaction analysis, mainly for pools of six donors. Prevalence and incidence 
were calculated. Three published formulae were applied to estimate the residual risk (the window 
period ratio model and the formulae recommended by the European Medicines Agency and the World 
Health Organization). 
Results. Overall, 12,258,587 blood donors and 21,808,352 donations were tested for HCV 
and HIV. The prevalence of HCV decreased from 110.3×105 to 58.9×105 in years 2009 and 2015, 
respectively, while that of HIV remained stable over time (15.5×105 vs 15.4×105). The incidence 
of HCV decreased from 3.19×105 in 2009 to 1.58×105 in 2015, while the incidence of HIV did not 
show any significant fluctuations (average incidence 4.39×105). The residual risk of a viraemic unit 
entering the blood supply was estimated to be 0.077×106 or 1 in 12,979,949 donations for HCV and 
0.521×106 or 1 in 1,917,250 for HIV, according to the window period ratio model, and lower with 
the other two formulae. 
Discussion. HCV infection has declined over time in both first-time and repeat donors, while the 
data for HIV infection are stable. All three methods employed in this study showed that the residual 
risk of transmitting HCV or HIV through an infected blood unit is currently very low in Italy, but 
there are considerable differences in estimates between methods. Thus, harmonisation of these 
methods is advisable.
Keywords: HCV, HIV, incidence, prevalence, transfusional residual risk.
Introduction
The risk of acquiring hepatitis C virus (HCV) 
or human immunodeficiency virus (HIV) through 
blood transfusion has drastically decreased since 
the introduction of nucleic acid testing (NAT) along 
with the previously implemented antigen/antibody-
based assays for blood screening and the adoption 
of restrictive criteria for donor selection. Following 
the serological and molecular screening of blood and 
blood components, in most countries the residual risk 
of transfusion-transmitted HCV and HIV infections 
has become too low for direct assessment through 
conventional approaches, such as prospective follow-up 
and retrospective look-back studies of blood recipients1,2. 
The risk of collecting an infected donation that is 
undetectable by screening tests is, therefore, presently 
calculated through mathematical modelling based on 
the incidence rate of HCV and HIV infections among 
donors and on the length of the window period of the 
viral infection, which is  the temporal gap spanning from 
the time point of donor infection to the first detectability 
of specific viral markers3-7. Importantly, this diagnostic 
window period consists of two phases: the so-called 
eclipse period during which the virus has already 
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infected the donor but is not yet detected in blood even 
by highly sensitive NAT, and the ramp-up phase during 
which the viral concentration increases exponentially 
in the blood (i.e., viraemic phase) until a peak/plateau 
is reached. Blood collected in the viraemic phase of the 
diagnostic window can potentially transmit infection to 
the transfused recipient if the circulating viral load is 
below the diagnostic sensitivity of the screening assay. 
Hence, the sensitivity of the screening test being used is 
crucial in determining the length of the window period 
and, consequently, in calculating the residual risk. 
Monitoring the residual risk of transfusion-transmitted 
infections (TTI) of a specific donor population through 
the collection of epidemiological data is a crucial step 
in assessing the preventive measures taken by national 
blood systems to assure the safety of their blood 
supplies. Thus, most industrialised countries maintain 
dedicated surveillance programmes on this issue. In 
this context, the European Medicines Agency (EMA) 
requires manufacturers of plasma-derived medicinal 
products to collect data on HCV and HIV, as well as 
hepatitis B virus (HBV), infections in order to ensure 
an adequate selection of donors of blood and plasma8. In 
addition, Blood Establishments which provide the raw 
material for industrial fractionation must comply with 
EMA requirements through continuous epidemiological 
surveillance, reporting and annual updating of the 
assessment of the residual risk of TTI in their donor 
populations. The World Health Organization (WHO) 
has also recently edited guidelines on the estimation of 
residual risk of transmitting infections by transfusion9. 
Both documents (issued by the EMA and WHO) provide 
simplified formulae to estimate the risk with any kind 
of screening methodology used.
In Italy, previous studies aimed at assessing the 
residual risk of TTI were either carried out before 
the implementation of NAT or did not include data of 
the nation's entire blood supply. Between 1999 and 
2001, Gonzalez et al.10 showed, using the incidence 
rate window period model in the pre-NAT era that the 
residual risk, estimated on nearly 90% of Italy's blood 
supply, was 1.9 infections per million donations for 
HIV, but higher for HCV (16.7 per million donations) 
and HBV (69.2 per million donations). More recently, 
Velati et al.11 published the results of a survey carried out 
between 2001 and 2006 estimating that the introduction 
of NAT had improved the safety of blood remarkably, 
reducing the risk to 2.5 for HCV, 1.8 for HIV and 57.8 
for HBV infectious blood units per million donations in 
the blood supply. For the same period the residual risk, 
calculated by the incidence/window period model, was 
0.1×106 for HCV and 0.8×106 for HIV12.
This study was undertaken with the aim of monitoring 
the prevalence and incidence of HCV and HIV infections 
among Italian blood donors and of estimating the trend of 
residual risk of these TTI over a 7-year period, from 2009 
to 2015, following implementation of mandatory NAT. 
Materials and methods
In Italy, haemovigilance data are collected and 
processed through a web-based national blood 
surveillance system (SISTRA, Sistema Informativo dei 
Servizi Trasfusionali). SISTRA, issued in 2007 by the 
Italian competent authority, the National Blood Centre 
(Centro Nazionale Sangue, CNS) of the Ministry of 
Health, is the system that manages all information related 
to blood activities carried out nationwide, with a specific 
section dedicated to epidemiological surveillance of 
donors: this section contains records concerning donors 
found to be positive for TTI by routine screening, as well 
as their demographic characteristics and risk factors.
In agreement with Italian law13, all donors are 
voluntary, unpaid donors and are classified as:
1. first-time donors: individuals whose blood/plasma is 
tested for the first time for markers of TTI without 
evidence of prior testing in the Italian blood system. 
These donors include two subsets:
 1.1 subjects considered in good health after clinical 
evaluation who were tested for TTI markers and 
donated blood (standard selection procedure);
 1.2 subjects clinically evaluated and tested for TTI 
markers, but who did not give blood and were 
allowed to donate only after an established 
period (pre-donation screening). 
2. Repeat donors, including: 
 2.1 individuals who donated blood, after clinical 
evaluation and screening for TTI, for whom 
previous donation(s) within the last 24 months 
had been found to be negative;
 2.2 subjects evaluated clinically and tested for TTI 
markers who donated for the first time after 
pre-donation screening.
For the purpose of epidemiological surveillance in 
this study, only the first-time donors of subgroup 1.1 
were considered for calculation. Subjects in subgroup 
1.2 were excluded because TTI markers always included 
serological testing, but not necessarily NAT, since no 
blood units were collected. 
The ratio between first time and repeat donors was 
assessed on a regional basis to detect possible inter-
regional variations in the epidemiological indices. 
Regions were grouped into three macro geographic 
areas: northern, central and southern/islands.
All donations reviewed in this study were tested for 
antibodies to HCV (anti-HCV), HCV RNA and HIV 
RNA. Approximately 80% of the donations were also 
tested for antibodies to HIV (anti-HIV1/2)/HIV antigen 
(Combo test) while the remaining 20% were tested for 
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anti-HIV1/2 only. Serological testing for anti-HCV, anti-
HIV1/2 and HIV1/2 antibodies/antigen was carried out 
using third- or fourth-generation immunoassays from 
different manufacturers, approved as meeting European 
Community requisites. During the 7-year period covered 
by this study, the Blood Establishments employed 
automated analysers, based on the chemiluminescence 
immunoassay principle, for the tests. Different 
amplification methods were used for NAT: transcription-
mediated amplification (Grifols, International S.A: Sant 
Cugat del Vallès, Barcelona, Spain; formerly Novartis 
Vaccines & Diagnostics) for testing individual donors 
(PROCLEIX Ultrio and PROCLEIX Ultrio Plus on 
Tigris platform, and Ultrio Elite on Panther platform) 
and polymerase chain reaction (Roche Molecular 
System, Branchburg, USA) for mini-pool testing of six 
donors (TaqScreen MPX and TaqScreen v2). During 
the years 2009-2012, nearly 3.7% of donations were 
examined by polymerase chain reaction COBAS 
Ampliscreen (Roche Diagnostics, Branchburg, USA) 
in pools of 10-24 samples. This method was abandoned 
in 2013. Confirmatory and/or supplemental testing was 
performed on all repeatedly reactive samples following 
a previously described algorithm11.
Donors considered positive for HCV or HIV 
included: (i) those found to be positive for both viral 
serology (i.e., anti-HCV, anti-HIV) and NAT, (ii) those 
who were NAT positive in the absence of serological 
markers and (iii) those who were NAT negative but with 
positive serology. 
Risk factors
Donors who resulted positive for TTI markers were 
recalled by the Transfusion Service where they had 
donated in order to undergo repeat testing and a post-
donation interview with a physician who asked specific 
questions about risk factors. All these data were then 
reported in the web-based national blood surveillance 
system.
Prevalence and incidence
Prevalence is the proportion of infections (both 
recent and past) identified at a specified point in time 
or over a specified time period in a defined population. 
Incidence is the rate of newly acquired infections over 
a specified time period in a defined population8. In this 
study, prevalence was calculated in the population of 
first-time donors as the rate between the number of 
positive donors on the total number of this population in 
the same period of time per 100,000 donors7. Concerning 
the incidence, literature reports different ways14 to 
calculate rates. For the epidemiological purpose of this 
study, incidence was calculated in the population of 
repeat donors as the number of positive subjects who 
had a previous negative donation or negative testing 
within the preceding 2 years, divided by the total number 
of donations from repeat donors in the study period 
per mean inter-donation interval expressed in years 
(= person-years at risk). Incidence is expressed as the 
number of new infected cases × 100,000 person-years 
at risk.
The 95% confidence intervals (95% CI) for estimated 
prevalence and incidence rates were calculated assuming 
a Poisson distribution of the observed cases.
Residual risk calculation 
Residual risk for each TTI infection or risk that 
an infected donor would give a donation that tested 
negative (window period risk) was evaluated using 
the incidence rate window period model, which is the 
model most applied in different blood donor populations 
in the world6,7,15-23. After the mathematical models 
initially proposed by Lackriz, Schreiber and Busch3,4,7, 
other authors introduced some risk model refinements24 
and two authoritative, international institutions have 
proposed simplified algorithms to evaluate the residual 
risk of transmitting an infection by transfusion therapy: 
the EMA8 and the WHO9. Thus, we decided to apply 
all these three models to the Italian data and compare 
the results. 
In this study, the "window period ratio method" was 
considered the reference method since we had used it 
in the past, making comparisons with previous data 
easier. Briefly, the residual risk is estimated, in first-time 
and repeat donors, multiplying the NAT yield rate (i.e. 
number of NAT-only positive cases/number donations 
screened) by the ratio between the infectious pre-NAT 
window period and that estimated as the time elapsing 
from NAT detectability and serological detectability.
Since different NAT screening methods have 
been employed in Italy during the 7-year period of 
observation, we calculated the duration of the NAT 
window period using data collected from our national 
inter-laboratory quality programme. Very briefly, every 
year, participants are asked to complete a questionnaire 
regarding the serological and NAT methods in use in 
each Blood Establishment. These data, integrated with 
those obtained through the National Haemovigilance 
System, allowed us to record, per year and for each 
Blood Establishment, the NAT method used, the 
number of units of blood tested and the positive results, 
subdivided by first-time and repeat donors. The weighted 
average pre-NAT infectious window period for the entire 
period of observation was estimated to be 4.74 days for 
HCV and 7.0 days for HIV. Thus, according to Busch 
et al.7 the ratios between the two window periods of 
interest were 4.74/53.6 days for HCV and 7.0/8.0 days 
for HIV, respectively.
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On the other hand, the EMA and WHO suggest 
estimating the residual risk as the product of the 
incidence and the window period (expressed in years) 
in which a new infection would be undetected, per 
million donations. The incidence is calculated as the 
number of new infections (NAT-only positives) among 
the repeat donors in the study period with a previous 
negative donation on the total number of repeat donors 
in the same study period. As far as the window period 
concerns, the EMA indicates that this is 8 days for HCV 
and 15 days for HIV, while the WHO indicates 5 days 
for HCV and 8 days for HIV.
Since the NAT-only rates for both first-time and 
repeat donors are available in Italy, the overall donor 
population residual risk was estimated as follows: (% 
first-time donors × first-time donor rate or incidence) + 
(% repeat donors × repeat donor rate or incidence). The 
residual risk is expressed per million donations.
The 95% CI for residual risk were calculated 
applying the described formulae to the extreme values 
of incidence 95% CI.
Results
Donors and donations
From January 2009 to December 2015, a total of 
12,258,587 blood donors (age range: 18-70 years; male 
to female ratio: 2.3) were tested for markers of HCV and 
HIV infection (Table I). Of these donors, 15.8% were 
first-time donors (male to female ratio: 1.7), and 84.2% 
were repeat donors (male to female ratio: 2.4). 
During the study period, the average ratio between 
repeat and first-time donors was 5.3 and no significant 
changes in the yearly repeat/first-time donor ratios 
were seen during the study period (data not shown). 
There were some inter-regional differences, with the 
proportions of RP donors being higher in northern 
regions of Italy than in southern regions (14.2 vs 3.0).
As reported in Table I, of the 21,808,352 blood 
donations tested for both HCV and HIV, 8.9% were 
given by first-time donors while 91.1% were given by 
repeat donors, with a general average of 1.78 units per 
donor per year. Repeat donors gave a mean number of 
1.92 donations per year (donation index) with an inter-
donation interval of 0.52 years. Fifty-four percent of 
the donations were tested using NAT polymerase chain 
reaction technology while the remaining 46% were tested 
by NAT transcription-mediated amplification technology. 
Overall, a total of 2,641 donors tested positive 
for viral markers. Of these, 1,949 were found among 
the 1,934,612 (100.7×105) first-time donors and the 
remaining 692 were found among the 10,323,975 repeat 
donors (6.7×105). Thus, the frequency of positivity 
for viral markers was 15-fold higher among first-time 
donors than among repeat donors.
Table I - Blood donors and donations tested for hepatitis C 
virus and human immunodeficiency virus in Italy, 
2009-2015.
Total n. of donors tested 12,258,587 
Age (range) 18-70 years
Age and gender distribution Age groups Male (%) Female (%)
18-25 11.3 18.9
26-35 18.9 20.2
36-45 30.0 26.5
46-55 26.8 23.5
56-65 12.3 10.5
>65 0.7 0.4
Male to female ratio 2.3
N. of FT donors tested 1,934,612 (15.8%)
Age and gender distribution Age groups Male (%) Female (%)
18-25 23.6 28.5
26-35 24.2 23.2
36-45 27.0 25.0
46-55 18.8 18.0
56-65 6.3 5.2
>65 0.1 0.1
Male to female ratio 1.7
N. of RP donors tested 10,323,975 (84.2%)
Age and gender distribution Age groups Male (%) Female (%)
18-25 9.4 16.6
26-35 18.0 19.6
36-45 30.4 26.8
46-55 28.1 24.8
56-65 13.3 11.7
>65 0.8 0.5
Male to female ratio 2.4
RP/FT donor ratio
North
Centre
South/Isles
Italy 
14.2
  3.4
  3.0
  5.3
Total n. of blood donations 
tested
21,808,352
N. of blood donations
from FT donors
1,934,612 (8.9%)
N. of blood donations
from RP donors  
19,873,740 (91.1%)
Donation index 
(mean donations per year)
1.78
RP donation index 
(mean donations per year)
1.92
Inter-donation interval 0.52 years
N. of donations tested by:
NAT PCR
NAT TMA
11,771,573 (54%)
10,036,779 (46%)
FT: first-time; RP: repeat; NAT: nucleic acid testing; PCR: polymerase 
chain reaction; TMA: transcription-mediated amplification.
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Prevalence of markers of hepatitis C virus and 
human immunodeficiency virus in first-time donors
During the study period the average prevalence of 
HCV and HIV markers in FT donors was 85.7×105 and 
15.0×105, respectively (Table II). The prevalence of HCV 
decreased from the year 2009 to 2015 from 110.3×105 to 
58.9×105 while the prevalence of HIV remained stable 
over time (15.5×105 in 2009 vs 15.4×105 in 2015). The 
prevalence of both HCV and HIV infections showed 
inter-regional differences (Online supplementary 
content, Table SI). As for HCV, rates of infection were 
significantly lower in northern and central Italy compared 
with those reported in southern Italy, while HIV rates 
were somewhat higher in central Italy compared to those 
reported in the northern and southern regions, but the 
differences were not statistically significant. 
As shown in Table III, most HCV- and HIV-
positive first-time donors were males (66.7 and 79.7%, 
respectively), with the former more frequently present 
(34.0%) in the 36- to 45-year age group and the latter 
peaking (34.0%) in the 26- to 35-year age group.
With regards to HCV-related risk factors, the most 
reported (22.7%) were parenteral risk factors (i.e., 
dental treatment, surgery, tattooing, piercing, etc); 9.2% 
had sexual risks (of these, 77.2% reported unprotected 
heterosexual exposure to multiple, occasional partners 
and 22.8% reported having male-to-male sex); 67.1% 
denied having any known risk factor. 
Sexual at-risk behaviours were most frequently 
(49.2%) reported among HIV-infected individuals (of 
these, 63.8% were heterosexuals and 36.2% were males 
who had sex with males), while no risk factors were 
identified in 39.6% of the positive first-time donors. 
The age and gender of subjects with no risk factors 
for HCV and HIV did not differ significantly from the 
age and gender of those with risk factors.
Incidence of markers of hepatitis C virus and human 
immunodeficiency virus infection in repeat donors 
As shown in Table IV, a total of 238 HCV-positive 
and 454 HIV-positive repeat donors were classified as 
seroconverters (incident cases) between 2009 and 2015. 
The average incidence of HCV during the 7-year study 
period was 2.30×105 and decreased from 3.19×105 in 
2009 to 1.58×105 in 2015, while the average incidence 
of HIV in the same period was 4.39×105, ranging 
from 3.74×105 in 2010 and 5.29×105 in 2012, with no 
significant yearly fluctuations.
The incidence of both HCV and HIV showed some 
inter-regional differences (Online supplementary 
content, Table SII). Higher rates of HCV infection were 
found in southern regions than in central and northern 
regions, while rates of HIV infection were lower in the 
northern parts of the country.
As shown in Table III, most (63%) HCV-infected 
repeat donors were males and belonged (31.5%) to 
the 36- to 45-year age group; those infected with HIV 
were mostly males (89.4%) and belonged (34.6%) to 
the 26- to 35-year age group. As far as risk factors 
concerns, 31.1% of HCV-infected repeat donors had 
Table II -  Prevalence of hepatitis C virus and human immunodeficiency virus infection among first-time donors in Italy, 
2009-2015. 
Year N. of FT donors HCV HIV
N. of positives Prevalence ×105 
(95% CI)
N. of positives Prevalence ×105 
(95% CI)
2009 264,635 292 110.3(98.0-123.7) 41
15.5
(11.1-21.0)
2010 281,153 303 107.8 (96.0-120.6) 33
11.7
(8.1-16.5)
2011 297,321 270 90.8 (80.3-102.3) 39
13.1
(9.3-17.9)
2012 287,380 231 80.4 (70.3-91.4) 43
15.0
(10.8-20.1)
2013 271,841 225 82.8 (72.3-94.3) 48
17.7
(13.0-23.4)
2014 265,543 180 67.8 (58.2-78.4) 46
17.3
(12.7-23.1)
2015 266,739 157 58.9 (50.0-68.8) 41
15.4
(11.0-20.8)
2009-2015 1,934,612 1,658* 85.7(81.6-89.9) 291*
15.0
(13.4-16.9)
*21 subjects were HCV and HIV co-infected.
FT: first-time; HCV: hepatitis C virus; HIV: human immunodeficiency virus; 95% CI: 95% confidence interval.
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Table III - Demographics characteristics and risk factors of first-time and repeat donors positive for markers of hepatitis C 
virus and human immunodeficiency virus in Italy, 2009-2015.
FT donors RP donors
HCV+ (n=1,658)
N (%)
HIV+ (n=291) 
N (%)
HCV (n=238)
N (%)
HIV+ (n=454)
N (%)
Gender
Male 1,106 (66.7) 232 (79.7) 150 (63) 406 (89.4)
Female 552 (33.3) 59 (20.3) 88 (37) 48 (10.6)
Age group
18-25 122 (7.3) 54 (18.6) 15 (6.3) 60 (13.2)
26-35 306 (18.5) 99 (34.0) 56 (23.6) 157 (34.6)
36-45 564 (34.0) 85 (29.2) 75 (31.5) 141 (31.1)
46-55 500 (30.2) 44 (15.1) 71 (29.8) 76 (16.7)
56-65 163 (9.8) 9 (3.1) 20 (8.4) 20 (4.4)
>65 3 (0.2) - 1 (0.4)
Risk factor*
Sexual, of whom: 171 (9.2) 163 (49.2) 41 (14.3) 311 (60.6)
Heterosexual 132 (77.2) 104 (63.8) 38 (92.7) 193 (62.1)
MSM 39 (22.8) 59 (36.2) 3 (7.3) 118 (37.9)
Parenteral, of whom: 425 (22.7) 36 (10.9) 89 (31.1) 50 (9.7)
Intravenous drug use 28 (6.6) 1 (2.8) 2 (2.2) -
Dental treatment 128 (30.1) 8 (22.2) 28 (31.5) 14 (28.0)
Surgery 124 (29.2) 2 (5.6) 25 (28.1) 13 (26.0)
Transfusion 37 (8.7) 11 (30.5) 2 (2.2) -
Others (tattoo, piercing, etc.) 108 (25.4) 14 (38.9) 32 (36.0) 23 (46.0)
Household contact 19 (1.0) 1 (0.3) 4 (1.4) 4 (0.8)
Not identified** 1,254 (67.1) 131 (39.6) 152 (53.2) 148 (28.9)
*Each case could report more than one risk factor. **Not identified  includes subjects (nearly 50%) who didn't return to complete the post-donation interview. 
FT: first-time; RP: repeat; HCV: hepatitis C virus; HIV: human immunodeficiency virus; MSM: males who have sex with males. 
Table IV - Incidence of hepatitis C virus and human immunodeficiency virus infections among repeat donors in Italy, 
 2009-2015.
Year N. of RP donors N. of RP 
donations
Person-
years*
HCV HIV
N. of 
positives
Incidence ×105 
(95% CI)
N. of positives Incidence ×105 
(95% CI)
2009 1,425,791 2,769,776 1,440,283 46 3.19
(2.34-4.26)
57 3.96
(3.00-5.13)
2010 1,441,350 2,824,685 1,468,836 37 2.52
(1.77-3.47)
55 3.74
(2.82-4.87)
2011 1,474,930 2,889,653 1,502,620 33 2.20
(1.51-3.08)
71 4.73
(3.69-5.96)
2012 1,501,319 2,905,769 1,511,000 34 2.25
(1.56-3.14)
80 5.29
(4.20-6.59)
2013 1,504,371 2,872,883 1,493,899 37 2.48
(1.74-3.41)
65 4.35
(3.36-5.55)
2014 1,487,313 2,816,234 1,453,265 28 1.93
(1.28-2.78)
62 4.27
(3.27-5.47)
2015 1,488,901 2,794,740 1,453,265 23 1.58
(1.00-2.37)
64 4.40
(3.39-5.62)
2009-2015 10,323,975 19,873,740 10,334,345 238 2.30
(2.02-2.6)
454 4.39
(4.00-4.82)
*We considered a donation index of 1.92 and an inter-donation interval of 0.52 years.  
RP: repeat; FT: first-time; HCV: hepatitis C virus; HIV: human immunodeficiency virus; 95% CI: 95% confidence interval. 
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parenteral factors, 14.3% reported sexual exposure (of 
these 92.7% were heterosexuals and 7.3% were males 
who had sex with males), while 53.2% did not report 
any risk factor. Among HIV-positive repeat donors, the 
most frequently (60.6%) reported risk factor was sexual 
exposure (62.1% heterosexuals and 37.9% males who 
had sex with males), while no risk factors were identified 
in 28.9% of the donors.
Yield of positive nucleic acid tests in Italy
During the 7 years of observation, 32 units of 
blood were identified as NAT-only positive: 19 units 
(8 collected from first-time and 11 from repeat donors) 
were found HCV RNA positive and anti-HCV antibody 
negative and 13 units (3 from first-time donors and 10 
from repeat donors) were HIV RNA positive and HIV-
antigen/antibody negative. Of the 19 HCV NAT-only 
positive subjects, 10 were males and 9 females (median 
age, 47 years), while of the 13 HIV NAT-only positive 
subjects 12 were males and 1 female with a median age 
of 32 years. All 32 infected donors detected as NAT-only 
cases seroconverted to anti-HCV and anti-HIV positivity 
during the follow up.
Estimated residual risk of hepatitis C virus and 
human immunodeficiency virus  
The results of the evaluation of residual risk for HCV 
and HIV in Italy obtained with the three methods are 
reported in Tables V and VI.
As shown in Table V, the residual risk of a non-
detected, but HCV viraemic unit was, for the entire 
examined period, 0.077×106 (or 1 in 12.98 million 
donations) according to the window period ratio model; 
0.034×106 (or 1 in 29.44 million donations) according to 
the EMA method and 0.021×106 (or 1 in 47.10 million 
donations) with the WHO method. 
In Table VI the same parameters are reported for 
HIV. In this case the window period ratio model gave a 
value of 0.52×106 (or 1 in 1.93 million units), while the 
EMA method gave a value of 0.043×106 (or 1 in 22.94 
million units) and the WHO method resulted in a value 
of 0.023 (or 1 in 43.02 million units). 
For both HCV and HIV infections, the residual 
risk values estimated by the EMA and WHO methods 
overlapped, but were significantly lower than the value 
obtained with Busch's method.
Discussion 
Blood has never been safer but the achievement of 
zero-risk for TTI remains a goal to pursue.
In the current epidemiological situation, the risk of 
transmitting an infection to the transfused recipient or 
of contaminating plasma pools used for manufacturing 
blood products is mainly due to the collection of a blood 
donation during the viraemic phase of the diagnostic 
window, whose length depends on the screening marker, 
the category of screening assay (NAT vs antibody or 
antigen-based assays), the sensitivity of the assay used 
and the replication kinetics of the virus during the early 
phase of infection. In this context, the implementation 
of highly sensitive NAT together with antigen/antibody-
based assays has provided an efficient, supplementary 
tool for further reducing the residual risk of transmitting 
HCV, HIV and HBV through blood transfusion.
HCV NAT screening of blood donations was 
implemented in Italy in 2002, while HIV NAT was first 
introduced in a few regions in 2002, and then became 
mandatory - together with HBV NAT - on a national 
scale in 2008. At present, according to the Italian law, all 
blood donations are tested for HBV DNA and HBsAg, 
HCV RNA and anti-HCV, HIV RNA and anti-HIV-1-2/
HIV antigen, and syphilis. In addition, donations are 
tested for West Nile virus during the at-risk period of 
the year. Furthermore, test screening is preceded by 
restrictive donor selection based on a physician-collected 
clinical history, including confidential unit exclusion, and 
behavioural screening based on individual risk assessment.
From the data in this study, the general trends of HCV 
and HIV infections in the Italian blood population seem 
quite different. The rate of HCV infection has diminished 
in both first-time donors (prevalence from 110.0×105 in 
2009 to 58.9×105 in 2015) and repeat donors (incidence 
from 3.19×105 in 2009 to 1.58×105 in 2015), while the 
rate of HIV infection remained stable over the years. 
Taken together, the frequency of viral positive markers 
was much higher (15-fold) among first-time donors 
than among repeat donors, a finding that is driving our 
National Blood Centre to progressive introduction of 
pre-donation screening and elimination of first-time 
donors who do not return to donate again.
The HCV- and HIV-infected donors show some 
demographic and risk behaviour differences, with the 
HCV-positive subjects being approximately 10 years 
older than those infected by HIV, a distribution that 
was observed in both first-time and repeat donors. 
Parenteral exposure (i.e., tattooing, piercing, dental 
treatments, surgery) was the main known risk factor 
reported in first-time donors (22.7%) as well as in 
repeat (31.1%) HCV-infected donors, followed by 
sexual at-risk behaviours (9.2 and 14.3%, respectively). 
It is worth noting that most first-time and repeat donors 
with sexual at-risk behaviours were heterosexuals 
who reported having unprotected exposure to multiple 
occasional partners (77.2 and 92.7%, respectively), 
while 22.8% of the former and 7.3% of the latter reported 
having male to male sex. Finally, it is of some concern 
that 67.1% of first-time donors and 53.2% of repeat 
donors reported no risk behaviours that, if detected 
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when compiling the case history, would have led them 
to exclusion from blood donation.  
As far as concerns HIV-infected donors, sexual 
behaviour was the most common risk factor: 49.2% 
in first-time donors and 60.6% in repeat donors with a 
heterosexual/males having sex with males ratio of 1.76 
among first-time donors and of 1.64 in repeat donors. 
This picture in Italy, where the criteria for blood donor 
selection are the same for men who have sex with men 
and heterosexuals and are based on individual risk 
assessment, is similar to that observed in the Italian 
non-donor HIV-infected population25,26, but differs from 
that reported in HIV-infected donors of a number of 
other countries27-30. 
Similarly to what was seen with HCV, a remarkable 
proportion of both first-time (39%) and repeat (29%) 
HIV-positive donors declared no known HIV-related risk 
factors. The large proportion of HCV- and HIV-infected 
donors who did not report any risk factor strongly 
indicates that the pre- and post-donation counselling 
procedures currently in place in several Blood 
Establishments need to be improved. Thus, a specific 
standardised questionnaire issued by our National Blood 
Centre has recently been mandated on a national scale 
together with the adoption of more stringent educational 
programmes targeted to convince at-risk donors to self-
defer and to provide truthful responses to the health 
history questions.
Of the over 21.8 million blood donations tested 
between 2009 and 2015, 19 were found to be HCV 
NAT-only positive and 13 were found to be HIV NAT-
only positive. All donors who donated these infected 
donations were identified in the viraemic window 
period since they seroconverted to anti-HCV or anti-
HIV during the follow up. Thus, the use of NAT has 
improved blood safety by averting the risk of entering 
0.87 (or 1 in 1,149,425) HCV-infected units and 0.59 
(or 1 in 1,667,852) HIV-infected units per million 
donations tested into the blood supply. Of importance, 
in the absence of other serological markers, the rate of 
NAT positivity in blood units collected from first-time 
donors was 7.4 times higher than the rate among units 
collected from repeat donors for HCV and 3 times for 
HIV. This current yield in detecting infectious blood 
by NAT before transfusion is somewhat lower than that 
previously reported in a similar 6-year survey carried 
out in Italy between 2001 and 200611. In particular, in 
the study by Velati et al. the NAT yield was estimated 
to be around 2.5 (or 1 in 450,000) HCV-infected units 
and 1.8 (or 1 in 555,555) HIV-infected units per million 
donations tested, which are values that are nearly 3 
times higher than those detected in the current survey 
for both infections. 
In this study, we estimated the residual risk of 
transmitting a unit of HIV- or HCV-infected blood using 
three models adopted by the scientific and professional 
community: the window period ratio method described 
by Busch et al.7, and those reported by the EMA8 
and by the WHO Expert Committee on Biological 
Standardisation9. Our findings indicate that the current 
residual risks of HCV and HIV are lower than earlier 
estimates11. For example, according to the window 
period ratio method, the overall residual risk of HCV 
changed from 1 unit per 10 million tested in 2001-2006 
to 1 unit per 12.98 million tested in 2009-2015, while 
for HIV the residual risk changed from 1 unit per 1.25 
million tested to 1 unit per 1.9 million tested in the same 
two periods of time. Current estimates of residual risk 
for both HCV and HIV were much lower using the EMA 
method (1 unit per 29.4 million tested for HCV and 1 unit 
per 22.9 million tested for HIV) or WHO method (1 unit 
per 47.1 million tested for HCV and 1 unit per 43 million 
tested for HIV). Assuming the residual risk estimates 
obtained with Busch's model as the worst scenario, 
we can say that in Italy the present risk of releasing a 
potentially infectious HCV or HIV donation missed by 
screening with current assays (NAT and serology) into 
the blood supply is negligible, if compared to the risk of 
everyday living31. These findings are reassuring when 
residual risk estimates are used to counsel patients about 
the risk of transfusion.
Conclusions
In conclusion, blood transfusion is extremely safe 
in Italy, though a residual risk of TTI remains, mainly 
because of imperfect risk behaviour-based donor 
selection and the persistence of a diagnostic window 
period that cannot yet be closed. Continued effort is 
required to maintain and further improve the high level 
of blood safety.
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